# Tesamorelin FAQ: Visceral Fat, IGF-1, Safety, and FDA Scope

> Tesamorelin FAQ: 22 direct, cited answers on belly-fat and visceral-fat effects, durability on discontinuation, IGF-1, half-life, side effects, contraindications, and FDA-approval scope.

Direct, cited answers to the questions people actually ask — what tesamorelin does, how much fat the trials measured, what happens when you stop, and where the FDA approval begins and ends.

## Will tesamorelin help me lose belly fat?

In the pivotal 26-week Phase 3 RCT of 412 HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% while placebo rose 5.0% [1]. The studied population was HIV-associated lipodystrophy; effects on general belly fat outside that population are not established by large trials, so this is a documented result, not a personal projection.

## How long does it take to see fat loss from tesamorelin?

Trials measured visceral-fat reduction over 26 weeks, with the reduction sustained at 52 weeks on continued dosing [1][2]. The 2026 five-RCT meta-analysis pooled visceral, trunk, and hepatic-fat changes across these multi-month treatment periods [13]. The effect is a months-long, imaging-measured shift — there is no published evidence for a rapid weeks-scale change.

## Does tesamorelin burn belly fat?

Tesamorelin selectively reduced visceral adipose tissue (the fat around the organs) in HIV-lipodystrophy trials by raising endogenous GH and IGF-1, which promote lipolysis [1]. It did not significantly change subcutaneous fat or BMI in those studies [1] — the effect is a redistribution measured by imaging, concentrated in visceral fat rather than overall weight.

## Does tesamorelin work for fat loss in non-HIV users?

Pivotal efficacy trials enrolled HIV-positive adults on antiretroviral therapy [1][2]. A small mechanistic study in 13 healthy men confirmed GH/IGF-1 elevation [4], but no large general-population fat-loss RCT has been completed, so non-HIV fat-loss efficacy is mechanistically plausible but not established by trial evidence.

## What happens when you stop taking tesamorelin? Does the fat come back?

In the 52-week program, visceral fat reaccumulated upon discontinuation [2], and the Phase 3 trial with a safety extension likewise reported reversal of the visceral-fat reduction after stopping [6]. The measured benefit was contingent on continued dosing — the imaging gains revert toward baseline once the drug is withdrawn.

## How much fat can I lose on tesamorelin?

The pivotal trial reported a 15.2% visceral-fat reduction at 26 weeks [1]; a pooled analysis of two Phase 3 RCTs found 3.9-fold greater odds of reducing visceral fat below 140 cm² versus placebo (95% CI 2.03–7.44) [10]. These magnitudes are from the studied HIV-lipodystrophy population, not a personal projection.

## What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone, GHRH(1-44), with an N-terminal trans-3-hexenoic acid group that resists DPP-IV cleavage [1]. It stimulates the body's own pulsatile GH and raises IGF-1, and is FDA-approved only to reduce excess abdominal fat in HIV-associated lipodystrophy [5].

## What does tesamorelin do?

It binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous growth-hormone secretion, which raises liver-produced IGF-1 and promotes lipolysis preferentially in visceral fat [4]. The FDA-approved use is reducing excess abdominal fat in HIV-associated lipodystrophy [5]; all other uses are off-label.

## Does tesamorelin increase the risk of diabetes or affect blood sugar?

In 13 healthy men, neither fasting glucose nor insulin-stimulated glucose uptake changed significantly [4]; over 52 weeks in HIV patients, glucose changes were not clinically significant [2]. GH-axis stimulation can perturb glucose modestly, so monitoring is described for people with prediabetes or dysglycemia.

## Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?

A 6-month JAMA RCT in antiretroviral-treated HIV adults reduced hepatic lipid by a net -2.9% alongside visceral-fat reduction [3]. NAFLD/MASLD effects have been studied as a research endpoint in the HIV population, not as an FDA-approved indication outside it.

## How does tesamorelin affect the liver in NAFLD?

In the JAMA HIV trial, tesamorelin reduced hepatic fat as visceral fat fell [3]; the proposed mechanism couples GH/IGF-1-driven lipolysis with hepatic gene-expression shifts (upregulated oxidative phosphorylation, downregulated inflammatory sets) [3]. Long-term liver-histology effects were noted as needing further study.

## Can tesamorelin reduce liver fat?

In the 6-month JAMA RCT of 50 HIV adults, tesamorelin produced a net hepatic-fat reduction of -2.9% (P=0.003) [3], and the 2026 five-RCT meta-analysis pooled hepatic-fat reduction at -4.28% [13]. Liver-fat reduction has been demonstrated as a research endpoint specifically in HIV-associated fatty liver.

## What is the half-life of tesamorelin?

Secondary sources (the FDA label, Mayo Clinic) describe a terminal half-life on the order of about 26–38 minutes. Despite that rapid plasma clearance, downstream IGF-1 elevation persists across the dosing interval, which supports once-daily administration [11].

## How long does tesamorelin stay in your system?

Plasma exposure is short: population-PK modeling estimated apparent clearance near 1,060 L/h with no clinically relevant demographic covariates [11]. The biological signal (IGF-1) outlasts plasma drug levels because tesamorelin stimulates episodic GH secretion rather than acting as a circulating reservoir [11].

## What are the side effects of tesamorelin?

The FDA label warns about stimulating endogenous GH and raising serum IGF-1; injection-site reactions are reported in the GH-secretagogue class. The NIH LiverTox monograph assigns a likelihood score of E (unlikely cause of clinically apparent liver injury), with no reported attributable liver-injury cases [5].

## Does tesamorelin cause water retention?

Fluid-related effects are part of the broader growth-hormone-class warning profile noted in the FDA label, which cautions about stimulating endogenous GH. The trial literature emphasizes visceral-fat and glucose endpoints [1][2] rather than isolating fluid retention as a measured outcome.

## Who should not take tesamorelin / who should avoid it?

The FDA prescribing label lists contraindications including any preexisting active malignancy (IGF-1 is a growth factor), known hypersensitivity to tesamorelin or its excipients, and pregnancy (animal studies showed hydrocephaly in offspring) [5]. It is also prohibited in sport under the WADA Prohibited List (category S2).

## Is tesamorelin FDA approved?

Yes, but only for one indication: tesamorelin was approved in the United States in 2010 (NDA 022505) to reduce excess abdominal fat in HIV-infected patients with antiretroviral-related lipodystrophy [5]. Every other use — cosmetic weight loss, anti-aging, non-HIV fat loss — is off-label.

## Does tesamorelin raise IGF-1 levels?

Yes. In 13 healthy men, tesamorelin raised IGF-1 by 181 µg/L (P<0.0001) [4]; in the pivotal HIV trial IGF-1 increased 81.0% [1]. IGF-1 elevation is the expected downstream signal of GH-axis stimulation and is the most consistent biomarker readout across the studies.

## How does tesamorelin stimulate growth hormone release?

It binds the GHRH receptor on pituitary somatotrophs and triggers cAMP/PKA signaling that drives pulsatile GH secretion [4]. Population PK-PD modeling confirmed tesamorelin stimulates GH in an episodic, pulse-like manner rather than continuously [11], which distinguishes its profile from recombinant growth hormone.

## Is tesamorelin a growth hormone?

No. Tesamorelin is a GHRH analogue, not growth hormone itself; it amplifies the body's own pulsatile GH rhythm rather than supplying exogenous GH [11]. That mechanism — triggering an internal pulse rather than clamping a continuous level — distinguishes its metabolic profile from recombinant growth hormone.

## How does tesamorelin work?

Tesamorelin activates the Gs/adenylyl-cyclase/cAMP/PKA cascade at the GHRH receptor, driving GH gene transcription and pulsatile GH release [4]. GH then stimulates hepatic IGF-1, and together they activate hormone-sensitive lipase to break down visceral fat [4] — the cascade detailed on the research page.

---

A terminal trace of the peer-reviewed tesamorelin record — every visceral-fat and IGF-1 figure returned green and sourced, the HIV-lipodystrophy-only scope and the reverts-when-you-stop caveat printed beside the value, never behind it; no clinic at this prompt and nothing here dosed, dispensed, or sold.